Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genomic coamplification of CDK4/MDM2/FRS2 is associated with very poor prognosis and atypical clinical features in neuroblastoma patients

22 Nov 2019

Abstract excerpt

Neuroblastoma (NB) is the most common extracranial malignant tumor of childhood and is characterized by a broad heterogeneity in clinical presentation and evolution. Recent advances in pangenomic analysis of NB have revealed different recurrent chromosomal aberrations. Indeed, it is now well established that the overall genomic profile is important for treatment stratification. In previous studies, 11 genes were...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer, Hypoxia, and Metabolism
Share to Lung Cancer Research Studies
Share to Neuroblastoma Research and Treatments

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 31756773
DOI: 10.1002/gcc.22827

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 19 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genomic coamplification of CDK4/MDM2/FRS2 is associated with very poor prognosis and atypical clinical features in neuroblastoma patientsPMID 31756773Read ↗

Characterization of amplicons in neuroblastoma: high-resolution mapping using DNA microarrays, relationship with outcome, and identification of overexpressed genes.Semantic proximity Read ↗

Amplification of CDK4 and MDM2: a detailed study of a high-risk neuroblastoma subgroupSemantic proximity Read ↗

Genomic profile of MYCN non-amplified neuroblastoma and potential for immunotherapeutic strategies in neuroblastomaSemantic proximity Read ↗

Identification of a novel recurrent 1q42.2‐1qter deletion in high risk <i>MYCN</i> single copy 11q deleted neuroblastomasSemantic proximity Read ↗

Molecular targeting therapies for neuroblastoma: Progress and challengesSemantic proximity Read ↗

Accumulation of potential driver genes with genomic alterations predicts survival of high-risk neuroblastoma patientsSemantic proximity Read ↗

Genomic profile of MYCN non-amplified neuroblastoma and potential for immunotherapeutic strategies in neuroblastoma.Semantic proximity Read ↗

Research progress of neuroblastoma related gene variations.Semantic proximity Read ↗

Genetics and genomics of neuroblastoma.Semantic proximity Read ↗

Association of heterogeneous MYCN amplification with clinical features, biological characteristics and outcomes in neuroblastoma: A report from the Children's Oncology GroupSemantic proximity Read ↗

Neuroblastomas have distinct genomic DNA profiles that predict clinical phenotype and regional gene expression.Semantic proximity Read ↗

Chromosome Imbalances in Neuroblastoma—Recent Molecular Insight into Chromosome 1p-deletion, 2p-gain, and 11q-deletion Identifies New Friends and Foes for the FutureSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.